XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2

Segment Information (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of segment information

		During the Three-Month Period Ended September 30, 2022
		Scours				Mastitis				Other				Total
Product sales		$	4,751,049			$	44,976			$	—			$	4,796,025
Costs of goods sold			2,898,897				45,441				5,636				2,949,974
Gross margin			1,852,152				(465	)			(5,636	)			1,846,051
OPERATING EXPENSES:
Product development expenses			6,421				1,246,243				17,097				1,269,761
Sales and marketing expenses			369,439				357,299				—				726,738
Administrative expenses			—				—				466,342				466,342
Operating expenses			375,860				1,603,542				483,439				2,462,841
NET OPERATING INCOME (LOSS)		$	1,476,292			$	(1,604,007	)		$	(489,075	)		$	(616,790	)

		During the Three-Month Period Ended September 30, 2021
		Scours				Mastitis				Other				Total
Product sales		$	5,033,428			$	35,736			$	81,009			$	5,150,173
Costs of goods sold			2,671,310				25,814				34,345				2,731,469
Gross margin			2,362,118				9,922				46,664				2,418,704
OPERATING EXPENSES:
Product development expenses			17,326				1,001,354				28,818				1,047,498
Sales and marketing expenses			496,010				160,408				—				656,418
Administrative expenses			—				—				443,698				443,698
Operating expenses			513,336				1,161,762				472,516				2,147,614
NET OPERATING INCOME (LOSS)		$	1,848,782			$	(1,151,840	)		$	(425,852	)		$	271,090

		Scours				Mastitis				Other				Total
Total Assets as of September 30, 2022		$	18,678,408			$	18,634,760			$	9,088,393			$	46,401,561
Total Assets as of September 30, 2021		$	14,070,880			$	19,310,110			$	10,850,473			$	44,231,463
Depreciation and amortization expense during the three-month period ended September 30, 2022		$	302,235			$	316,317			$	15,688			$	634,240
Depreciation and amortization expense during the three-month period ended September 30, 2021		$	259,993			$	344,554			$	15,579			$	620,126
Capital Expenditures during the three-month period ended September 30, 2022		$	665,825			$	21,032			$	47,452			$	734,309
Capital Expenditures during the three-month period ended September 30, 2021		$	477,844			$	193,561			$	3,995			$	675,400

		During the Nine-Month Period Ended September 30, 2022
		Scours				Mastitis				Other				Total
Product sales		$	14,537,390			$	118,237			$	1,455			$	14,657,082
Costs of goods sold			7,870,420				104,092				25,967				8,000,479
Gross margin			6,666,970				14,145				(24,512	)			6,656,603
OPERATING EXPENSES:
Product development expenses			23,025				3,331,311				90,128				3,444,464
Sales and marketing expenses			1,127,676				1,069,801				—				2,197,477
Administrative expenses			—				—				1,679,851				1,679,851
Operating expenses			1,150,701				4,401,112				1,769,979				7,321,792
NET OPERATING INCOME (LOSS)		$	5,516,269			$	(4,386,967	)		$	(1,794,491	)		$	(665,189	)

		During the Nine-Month Period Ended September 30, 2021
		Scours				Mastitis				Other				Total
Product sales		$	13,529,846			$	102,977			$	166,306			$	13,799,129
Costs of goods sold			7,559,174				73,864				70,877				7,703,915
Gross margin			5,970,672				29,113				95,429				6,095,214
OPERATING EXPENSES:
Product development expenses			24,892				2,837,830				215,948				3,078,670
Sales and marketing expenses			1,279,673				334,324				—				1,613,997
Administrative expenses			—				—				1,290,574				1,290,574
Operating expenses			1,304,565				3,172,154				1,506,522				5,983,241
NET OPERATING INCOME (LOSS)		$	4,666,107			$	(3,143,041	)		$	(1,411,093	)		$	111,973

		Scours				Mastitis				Other				Total
Total Assets as of September 30, 2022		$	18,678,408			$	18,634,760			$	9,088,393			$	46,401,561
Total Assets as of September 30, 2021		$	14,070,880			$	19,310,110			$	10,850,473			$	44,231,463
Depreciation and amortization expense during the nine-month period ended September 30, 2022		$	895,045			$	946,878			$	47,144			$	1,889,067
Depreciation and amortization expense during the nine-month period ended September 30, 2021		$	756,714			$	1,062,703			$	46,403			$	1,865,820
Capital Expenditures during the nine-month period ended September 30, 2022		$	2,050,107			$	387,536			$	47,452			$	2,485,095
Capital Expenditures during the nine-month period ended September 30, 2021		$	1,055,412			$	840,675			$	7,968			$	1,904,055

		During the Year Ended December 31, 2021
		Scours				Mastitis				Other				Total
Product sales		$	18,933,092			$	143,280			$	166,597			$	19,242,969
Costs of goods sold			10,411,936				99,957				75,147				10,587,040
Gross margin			8,521,156				43,323				91,450				8,655,929
OPERATING EXPENSES:
Product development expenses			25,374				3,887,781				255,363				4,168,518
Sales and marketing expenses			1,942,391				561,535				—				2,503,926
Administrative expenses			—				—				1,726,100				1,726,100
Operating expenses			1,967,765				4,449,316				1,981,463				8,398,544
NET OPERATING INCOME (LOSS)		$	6,553,391			$	(4,405,993	)		$	(1,890,013	)		$	257,385

		During the Year Ended December 31, 2020
		Scours				Mastitis				Other				Total
Product sales		$	15,072,446			$	136,210			$	133,548			$	15,342,204
Costs of goods sold			8,285,073				119,329				74,976				8,479,378
Gross margin			6,787,373				16,881				58,572				6,862,826
OPERATING EXPENSES:
Product development expenses			106,393				4,022,712				225,522				4,354,627
Sales and marketing expenses			2,119,289				48,610				—				2,167,899
Administrative expenses			—				—				1,720,653				1,720,653
Operating expenses			2,225,682				4,071,322				1,946,175				8,243,179
NET OPERATING INCOME (LOSS)		$	4,561,691			$	(4,054,441	)		$	(1,887,603	)		$	(1,380,353	)

		Scours				Mastitis				Total
Total Assets as of December 31, 2021		$	22,442,944			$	22,022,744			$	44,465,688
Total Assets as of December 31, 2020		$	18,416,157			$	21,933,437			$	40,349,594
Depreciation and amortization expense during the year ended December 31, 2021		$	1,094,810			$	1,374,171			$	2,468,981
Depreciation and amortization expense during the year ended December 31, 2020		$	1,002,360			$	1,447,647			$	2,450,007
Capital Expenditures during the year ended December 31, 2021		$	1,655,866			$	952,783			$	2,608,649
Capital Expenditures during the year ended December 31, 2020		$	3,456,307			$	616,232			$	4,072,539

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration